How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3) [0.03%]
如何开展为医疗决策提供依据的经济学评价系统评审（一）——五步工作法
Ghislaine A P G van Mastrigt,Mickaël Hiligsmann,Jacobus J C Arts et al.
Ghislaine A P G van Mastrigt et al.
Systematic reviews of economic evaluations are useful for synthesizing economic evidence about health interventions and for informing evidence-based decisions. Areas covered: As there is no detailed description of the methods for performing...
How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3) [0.03%]
临床实践指南的系统评价之经济评估的选择与检索策略开发（第2部分）
F W Thielen,Gapg Van Mastrigt,L T Burgers et al.
F W Thielen et al.
This article is part of the series "How to prepare a systematic review of economic evaluations (EES) for informing evidence-based healthcare decisions", in which a five-step approach is proposed. Areas covered: This paper focuses on the sel...
How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3) [0.03%]
如何开展经济学评价的系统评价（III）：资料提取、偏倚风险和适用性评估
Bfm Wijnen,Gapg Van Mastrigt,W K Redekop et al.
Bfm Wijnen et al.
This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: ...
Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance [0.03%]
中国城镇职工基本医疗保险制度下监管竞争对医药价格的影响分析
Mingyue Zhao,Jing Wu
Mingyue Zhao
Background: Examine the effects of regulated competition on the drug pricing in China. Methods: Based on product-level data, a regressi...
Taehwan Park,Chang-Ju Choi,Yeera Choi et al.
Taehwan Park et al.
Cetuximab is a novel biological agent with superior therapeutic efficacy for colorectal cancer treatment. This study aimed to systematically review the existing evidence related to the cost-effectiveness of cetuximab. Areas covered: Using M...
Hepatitis C: how has France limited the expenses related to new treatments? [0.03%]
法国如何限制与新型药物治疗丙型肝炎相关的费用？
Anne-Laure Mouterde,François Bocquet,Isabelle Fusier et al.
Anne-Laure Mouterde et al.
The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá [0.03%]
并存疾病对波哥大临床环境中HIV患者成本、效用及健康相关生活质量的影响
Mark Jm Van Duin,Rafael Conde,Ben Wijnen et al.
Mark Jm Van Duin et al.
Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. ...
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis [0.03%]
维多珠单抗治疗中至重度活动性溃疡性结肠炎的成本效益分析的综述研究
Her Hsin Tsai,Christopher Black
Her Hsin Tsai
Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigati...
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C [0.03%]
索磷布韦维帕他韦治疗慢性丙型肝炎患者的报告结果和经济成果分析
Linda Henry,Zobair Younossi
Linda Henry
We used published literature from 2013-2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA's) treatment regimens. Areas covered: Specifically, this paper will address DAA's clinical eff...
Corrigendum [0.03%]
勘误表